Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828908 | 0.89 | ROCK2 (0.62) | SMN1; SMN2RAB9ANPC1HDAC2HDAC8 | |
| SCHEMBL2844665 | 0.89 | KDM4E (0.54) | SMN1; SMN2RAB9ANPC1HDAC2HDAC8 | |
| SCHEMBL2846899 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9ANPC1HDAC2HDAC8 | |
| SCHEMBL2840635 | 0.85 | TRPV1 (0.53) | SMN1; SMN2RAB9ANPC1HDAC2HDAC8 | |
| SCHEMBL334624 | 0.85 | TRPV1 (0.53) | SMN1; SMN2RAB9ANPC1HDAC2HDAC8 | |
| SCHEMBL23291316 | 0.84 | EPHX2 (0.67) | SMN1; SMN2RAB9ANPC1HDAC2HDAC8 | |
| SCHEMBL23928112 | 0.83 | RAB9A (0.61) | SMN1; SMN2RAB9ANPC1HDAC2HDAC8 | |
| SCHEMBL23291153 | 0.83 | EPHX2 (0.53) | SMN1; SMN2RAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL424305 | 0.82 | KDM4E (0.65) | SMN1; SMN2RAB9ANPC1HDAC2HDAC8 | |
| SCHEMBL424304 | 0.82 | HDAC2 (0.58) | SMN1; SMN2RAB9ANPC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102498095-A | Indoline derivatives | TOKYO INST TECH | 2012-06-13 | — | — | CN | claimed |
| EP-1567497-B1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2009-09-23 | — | — | EP | claimed |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | claimed |
| CN-114751920-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114736219-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4377298-A1 | PROTEIN SECRETION INHIBITORS | Gate Bioscience, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-118139851-A | Antitumor compounds | 法马马有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117865987-A | Antitumor compounds | 法马马有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-02 | — | — | US | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023010051-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2007061554-A2 | DOSAGE OF 4-AMINOPYRIDINE DERIVATIVES FOR TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES | PURDUE RESEARCH FOUNDATION (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1605938-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| EP-1605938-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-12-21 | — | — | EP | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| WO-2004087145-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | SMN1; SMN2 388/4885RAB9A 4678/4885NPC1 1326/4885 |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | P2RY4, INA, PMP22 | SMN1; SMN2 15/4885RAB9A 3684/4885NPC1 4768/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | SMN1; SMN2 388/4885RAB9A 4678/4885NPC1 1326/4885 |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | TTR, MAP1LC3B, SAAL1 | SMN1; SMN2 894/4885RAB9A 3384/4885NPC1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.